Document:

Warrant to Purchase Stock

 Exhibit 4.3 
 Confidential Treatment Requested by Extend Health, Inc. 
 THIS WARRANT AND THE
UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION
PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY. 

WARRANT TO PURCHASE SHARES OF COMMON STOCK 
 of 
 EXTEND HEALTH, INC. 

Dated as of August 15, 2011 
 Void after the date specified in Section 8 
 No. 0001

 THIS CERTIFIES THAT, in connection with the execution by Extend Health, Inc. and Towers Watson
Pennsylvania Inc. of that certain Preferred Sales Referral Agreement, dated April 12, 2011 (the “Referral Agreement”), Towers Watson Pennsylvania Inc., or its registered assigns (the “Holder”), is
entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Extend Health, Inc., a Delaware corporation (the “Company”), duly authorized, validly issued, fully paid and
nonassessable shares of the Company’s Common Stock, $0.001 par value per share (“Shares”), in the amounts, at such times and at the price per Share set forth in Section 1 and Schedule 1 hereto. The term
“Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. 
 The following is a statement of the rights of the Holder and the conditions to which this Warrant is subject, and to which Holder, by acceptance of this Warrant, agrees: 

1.    Number and Price of Shares; Exercise Period. 

(a)    Number of Shares. Subject to any previous exercise of the Warrant, the Holder
shall have the right to purchase up to such number of Shares as shall be calculated pursuant to Schedule 1 hereto, prior to the expiration of this Warrant as provided in Section 8. 

(b)    Exercise Price. The exercise price per Share shall be equal to $10.00, subject
to adjustment pursuant hereto (the “Exercise Price”). 

(c)    Exercise Period. This Warrant shall be exercisable, in whole or in part, after
the sales targets set forth on Schedule 1 hereto have been achieved by Holder pursuant to the Referral Agreement (the “Sales Targets Achievement”) for the number of Shares set forth on Schedule 1 hereto. If this
Warrant is exercised (i) in conjunction with the commencement by the Company of a road show in connection with its initial public offering (the “Road Show”), the determination as to the occurrence of the Sales Targets

  
 [***] Information has been omitted and filed
separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Confidential Treatment Requested by Extend Health, Inc. 

 
 
Achievement (the “Determination Date”) shall be made as of 5:00 p.m. Pacific Time on the date that is five (5) business days prior to the commencement by the Company
of the Road Show, such date to be reasonably determined in good faith by the Company; (ii) in connection with a transaction described in Section 8(c) hereof, the Determination Date shall be as of 5:00 p.m. Pacific Time on the date that is
five (5) business days prior to the effective date of such transaction, such date to be reasonably determined in good faith by the Company; or (iii) other than in connection with the events described in the preceding clauses (i) and
(ii), the Determination Date shall be as of 5:00 p.m. Pacific Time on the date that is five (5) business days prior to exercise; provided, that in the case of clause (iii) only, such exercise may not occur prior to December 31,
2011. 
 2.    Exercise of the Warrant. 

(a)    Exercise. The purchase rights represented by this Warrant may be exercised at
the election of the Holder, in whole or in part, in accordance with Section 1, by: 

(i)    the tender to the Company at its principal office (or such other office or agency as the
Company may designate) of a notice of exercise in the form of Exhibit A (the “Notice of Exercise”), duly completed and executed by or on behalf of the Holder, together with the surrender of this Warrant; and 

(ii)    the payment to the Company of an amount equal to (x) the Exercise Price multiplied by
(y) the number of Shares being purchased, by wire transfer or certified, cashier’s or other check reasonably acceptable to the Company and payable to the order of the Company. 

(b)    Stock Certificates. The rights under this Warrant shall be deemed to have been
exercised and the Shares issuable upon such exercise shall be deemed to have been issued immediately prior to the close of business on the date this Warrant is exercised in accordance with its terms, and the person entitled to receive the Shares
issuable upon such exercise shall be treated for all purposes as the holder of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after such date, the Company shall issue and deliver to the
person or persons entitled to receive the same a certificate or certificates for that number of Shares issuable upon such exercise. In the event that the rights under this Warrant are exercised in part and the remaining rights have not expired, the
Company shall execute and deliver a new duly authorized and validly issued Warrant reflecting the number of Shares that remain subject to this Warrant. 
 (c)    No Fractional Shares or Scrip. No fractional Shares or scrip representing fractional Shares shall be issued upon the exercise of the rights under this Warrant. In
lieu of such fractional Share to which the Holder would otherwise be entitled, the Company shall make a cash payment to the Holder equal to the Exercise Price multiplied by such fraction. 

3.    Replacement of the Warrant. Subject to the receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company or, in the case of
mutilation, on surrender and cancellation of the mutilated Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of the surrendered and cancelled Warrant, a new Warrant of like tenor and amount. 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 2 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 4.    Transfer of the
Warrant. 
 (a)    Warrant Register. The Company shall maintain a register
(the “Warrant Register”) containing the name and address of the Holder or Holders. Until this Warrant is transferred on the Warrant Register in accordance herewith, the Company may treat the Holder as shown on the Warrant
Register as the absolute owner of this Warrant for all purposes, notwithstanding any notice to the contrary. The Holder of this Warrant (or of any portion of this Warrant) may change its address as shown on the Warrant Register by delivering written
notice to the Company. 
 (b)    Warrant Agent. The Company may appoint an
agent for the purpose of maintaining the Warrant Register referred to in Section 4(a), issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant, replacing this Warrant or
conducting related activities. 
 (c)    Transferability of the Warrant.
Subject to the provisions of this Warrant with respect to compliance with the Securities Act of 1933, as amended (the “Securities Act”) and limitations on assignments and transfers, including, without limitation, compliance
with the restrictions on transfer set forth in Section 5, title to this Warrant may be transferred by the endorsement (through the execution by the transferor and the transferee of the assignment form attached as Exhibit B (the
“Assignment Form”) and delivery of this Warrant in the same manner as a negotiable instrument transferable by endorsement and delivery. 
 (d)    Exchange of the Warrant upon a Transfer. On surrender of this Warrant (and a properly endorsed Assignment Form) for exchange, subject to the provisions of this
Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue a new Warrant or Warrants of like tenor in the name of the Holder or in such other name(s) as the Holder (on payment by
the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise hereof, and the Company shall register any such transfer upon the Warrant Register. This Warrant (and the securities issuable upon exercise of
this Warrant) must be surrendered to the Company or its warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge, hypothecation or other transfer of any interest in any of the securities represented hereby. 

(e)    Taxes. In no event shall the Company be required to pay any tax which may be
payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to issue or deliver any such certificate unless and until the person or persons
requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the reasonable satisfaction of the Company that such tax has been paid or is not payable. 

5.    Restrictions on Transfer of the Warrant and Shares; Compliance with Securities Laws. By
acceptance of this Warrant, the Holder agrees to comply with the following: 

(a)    Restrictions on Transfers. This Warrant may not be transferred or assigned in
whole or in part without the Company’s prior written consent (which shall not be unreasonably withheld), and any attempt by Holder to transfer or assign any rights, duties or obligations that arise under this Warrant without such consent shall
be void. Any transfer of this Warrant or the Shares (the “Securities”) must be in compliance with all applicable federal and state securities laws. The Holder agrees not to make any sale, assignment, transfer, pledge or other
disposition of all or any portion of the Securities, or any beneficial interest therein, unless and until the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Securities subject to, and to be bound by,
the terms and conditions set forth in this Warrant to the same extent as if the transferee were the original Holder hereunder, and 
 (i)    there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration
statement, or 
  
 [***] Information has been omitted
and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 3 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 (ii)    (A) such
Holder shall have given prior written notice to the Company of such Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition,
(B) the transferee shall have confirmed to the reasonable satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Securities are being acquired (i) solely for the transferee’s own account and
not as a nominee for any other party, (ii) for investment and (iii) not with a view toward distribution or resale, and shall have confirmed such other matters related thereto as may be reasonably requested by the Company, and (C) if
requested by the Company, such Holder shall have furnished the Company, at the Holder’s expense, with an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such
Securities under the Securities Act, whereupon such Holder shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the Holder to the Company. 

(b)    Permitted Transfers. This Warrant may be transferred (i) if such transfer
does not involve a change in beneficial ownership, or (ii) in a transaction or transactions involving the distribution without consideration of Securities by any Holder to (x) a parent, subsidiary or other affiliate of a Holder, or
(y) any of the Holder’s partners, members or other equity owners, or retired partners or members, or to the estate of any of its partners, members or other equity owners or retired partners or members; provided, in each case, that
the Holder shall give written notice to the Company of the Holder’s intention to effect such disposition and shall furnish the Company with a detailed description of the manner and circumstances of the proposed disposition. 

(c)    Investment Representation Statement. Unless the rights under this Warrant are
exercised pursuant to an effective registration statement under the Securities Act that includes the Shares with respect to which the Warrant was exercised, it shall be a condition to any exercise of the rights under this Warrant that the Holder
shall have confirmed to the reasonable satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Shares so purchased are being acquired solely for the Holder’s own account and not as a nominee for any other
party, for investment and not with a view toward distribution or resale. 

(d)    Securities Law Legend. The Securities shall (unless otherwise permitted by the
provisions of this Warrant) be stamped or imprinted with a legend substantially similar to the following (in addition to any legend required by state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH
APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH
THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED
HEREBY. 
  
 [***] Information has been omitted and
filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 4 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 (e)    Market
Stand-off Legend. The Shares shall also be stamped or imprinted with a legend in substantially the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO
WHICH THESE SHARES WERE ISSUED, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. 

(f)    Instructions Regarding Transfer Restrictions. The Holder consents to the Company
making a notation on its records and giving instructions to any transfer agent in order to implement the restrictions on transfer established in this Section 5. 

(g)    Removal of Legend. The legend referring to federal and state securities laws
identified in Section 5(d) stamped on a certificate evidencing the Shares and the stock transfer instructions and record notations with respect to such securities shall be removed and the Company shall issue a certificate without such legend to
the holder of such securities if (i) such securities are registered under the Securities Act, or (ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of
such securities may be made without registration or qualification. 
 6.
    Adjustments. Subject to the expiration of this Warrant pursuant to Section 8, the number and kind of shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as
follows: 
 (a)    Adjustment to Exercise Price and Number of Shares Issuable Upon
Exercise of this Warrant Upon Dividend, Subdivision or Combination of Shares. If the Company shall, at any time or from time to time after August 15, 2011 (the “Original Issue Date”), (i) pay a dividend or
make any other distribution upon the Shares or any other capital stock of the Company payable in Shares, or (ii) subdivide (by any stock split, recapitalization or otherwise) its outstanding Shares into a greater number of Shares, the Exercise
Price in effect immediately prior to any such dividend, distribution or subdivision shall be proportionately reduced and the number of Shares issuable upon exercise of this Warrant shall be proportionately increased. If the Company at any time
combines (by combination, reverse stock split or otherwise) its outstanding Shares into a smaller number of Shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased and the number of Shares
issuable upon exercise of this Warrant shall be proportionately decreased. Any adjustment under this Section 6(a) shall become effective at the close of business on the date the dividend, subdivision or combination becomes effective.

 (b)    Adjustment to Exercise Price and Number of Shares Issuable Upon Exercise of
this Warrant Upon Consolidation, Reclassification, Merger or Reorganization. If at any time there shall be any reorganization, reclassification, recapitalization, merger, consolidation, or other similar transaction (other than any such
transaction covered by Section 6(a)) (a “Reorganization”) involving the Company (other than as otherwise provided for herein or as would cause the expiration of this Warrant under Section 8) in which shares of the
Company’s stock are converted into or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision shall be made so that the Holder shall thereafter be entitled to receive upon exercise of this
Warrant, the kind and amount of securities, cash or other property of the successor entity resulting from such Reorganization, equivalent in value to that which a holder of the Shares deliverable upon exercise of this Warrant would have been
entitled in such Reorganization if the right to purchase the Shares hereunder had been exercised immediately prior to such Reorganization. In any such case, appropriate adjustment (as determined in good faith by the Board of Directors of the
successor corporation) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such Reorganization such that the provisions of this Warrant shall be applicable after the
Reorganization, as near as reasonably may be, in relation to any shares or other securities deliverable after such Reorganization upon the exercise of this Warrant. The provisions of this Section 6(b) shall similarly apply to successive
Reorganizations. 
  
 [***] Information has been
omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 5 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 (c)    Notice of
Adjustments. Upon any adjustment in accordance with this Section 6, the Company shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the number of
securities or other property purchasable upon the exercise of the rights under this Warrant, setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish or cause to be
furnished to such Holder a certificate setting forth (i) such adjustments, (ii) the Exercise Price at the time in effect and (iii) the number of securities and the amount, if any, of other property that at the time would be received
upon exercise of this Warrant. 
 7.    Notification of Certain Events. Prior to the
expiration of this Warrant pursuant to Section 8, in the event that the Company shall authorize: 

(a)    the voluntary liquidation, dissolution or winding up of the Company; or 

(b)    any transaction resulting in the expiration of this Warrant pursuant to Section 8(b) or
8(c); 
 the Company shall deliver to the Holder of this Warrant at least seven (7) business days prior written notice
(i) of the expected effective date of any event specified in clause (a), (ii) of the date on which the Road Show shall commence, or (iii) of the effective date of an event that is described in Section 8(c), as applicable. The
notice provisions set forth in this section may be shortened or waived prospectively or retrospectively by the consent of the Holder of this Warrant. 
 8.    Expiration of the Warrant. This Warrant shall expire and shall no longer be exercisable as of the earliest to occur of: 

(a)    5:00 p.m., Pacific Time, on July 15, 2012; 

(b)    the date that is two (2) business days prior to the commencement by the Company of the
Road Show; provided, for the avoidance of doubt, that if the Company does not actually commence a Road Show this Warrant shall not be deemed to have expired pursuant to this clause (b); or 

(c)    the effective date of (i) the acquisition of the Company by another entity by means of
any transaction or series of related transactions to which the Company is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding any sale of stock for capital raising purposes and any
transaction effected primarily for purposes of changing the Company’s jurisdiction of incorporation) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately
prior to such transaction or series of related transactions retain, immediately after such transaction or series of transactions, as a result of shares in the Company held by such holders prior to such transaction or series of transactions, at least
a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately
following such acquisition, its parent), or (ii) a sale, lease or other disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by means of any transaction or series of related transactions,
except where such sale, lease or other disposition is to a wholly-owned subsidiary of the Company. 
  
 [***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 6 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 9.    No Rights as a
Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company or to be deemed the holder of any securities that may at any time be issuable on the exercise of the rights hereunder for any purpose
nor shall anything contained herein be construed to confer upon the Holder, as such, any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate
action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or any other rights of a stockholder of the Company, except as provided for in this Warrant, until the rights under the Warrant shall have been exercised and the Shares purchasable upon exercise of the rights
hereunder shall have become deliverable as provided herein. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. 
 10.    Market Stand-off. 

(a)    With respect to fifty percent (50%) of the Shares that may be received upon exercise of
this Warrant, the Holder of this Warrant hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic
effect as a sale, of any Shares (or other securities) of the Company held by the Holder (other than those included in a registration statement) during the one hundred eighty (180) day period following the effective date of the registration
statement for the Company’s initial public offering filed under the Securities Act (or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other
distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments
thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a
transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each certificate with a legend as substantially set forth in Section 5(e) with respect to the Shares
(or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day (or other) period. The Holder agrees to execute a market stand-off agreement with the underwriters in the offering in customary form
consistent with the provisions of this section. 
 (b)    With respect to the remaining
fifty percent (50%) of the Shares that may be received upon exercise of this Warrant, the Holder of this Warrant hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of,
or enter into any hedging or similar transaction with the same economic effect as a sale, of any Shares (or other securities) of the Company held by the Holder (other than those included in the registration) during the twelve (12) month period
following the effective date of the registration statement for the Company’s initial public offering filed under the Securities Act (or such other period as may be requested by the Company or an underwriter to accommodate regulatory
restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE
Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each certificate with a legend as
substantially set forth in Section 5(e) with respect to the Shares (or other securities) subject to the foregoing restriction until the end of such twelve (12) month (or other) period. 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 7 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 11.    Representations
and Warranties of the Holder. By acceptance of this Warrant, the Holder represents and warrants to the Company as follows: 
 (a)    No Registration. The Holder understands that the Securities have not been, and will not be, registered under the Securities Act by reason of a specific exemption
from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder’s representations as expressed herein or
otherwise made pursuant hereto. 
 (b)    Investment Intent. The Holder is
acquiring the Securities for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. The Holder has no present intention of selling, granting any participation
in, or otherwise distributing the Securities, nor does it have any contract, undertaking, agreement or arrangement for the same. 
 (c)    Investment Experience. The Holder has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to
the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating the merits and risks of its investment in the Company and protecting its own interests. 

(d)    Speculative Nature of Investment. The Holder understands and acknowledges that
the Company has a limited financial and operating history and that the Holder’s investment in the Company is highly speculative and involves substantial risks. The Holder can bear the economic risk of its investment and is able, without
impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 
 (e)    Access to Data. The Holder has had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Holder
believes that it has received all the information that it considers necessary or appropriate for deciding whether to acquire the Securities. The Holder understands that any such discussions, as well as any information issued by the Company, were
intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Holder acknowledges that any business plans prepared by the Company have been, and continue to be,
subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary
significantly from actual results. 
 (f)    Accredited Investor. The Holder
is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status as may be reasonably
requested by the Company. 
 (g)    Residency. The residency of the Holder
(or, in the case of a partnership or corporation, such entity’s principal place of business) is correctly set forth on the signature page hereto. 
 (h)    Restrictions on Resales. The Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Securities Act or an
exemption from such registration is available. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act, which permit resale of shares purchased in a private placement subject to the satisfaction of certain
conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not less than a specified period after a party has purchased and paid for the security to be sold; the
number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s transaction,” a transaction directly with a “market maker” or a “riskless
principal transaction” (as those terms are defined in the Securities Act or the Securities 
  
 [***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 8 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Holder acknowledges and understands that the
Company may not be satisfying the current public information requirement of Rule 144 at the time the Holder wishes to sell the Securities and that, in such event, the Holder may be precluded from selling the Securities under Rule 144 even
if the other applicable requirements of Rule 144 have been satisfied. The Holder acknowledges that, in the event the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration
will be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities
received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons
and the brokers who participate in the transactions do so at their own risk. 

(i)    No Public Market. The Holder understands and acknowledges that no public market
now exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 

(j)    Brokers and Finders. The Holder has not engaged any brokers, finders or agents
in connection with the Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with the Securities. 
 (k)    Legal Counsel. The Holder
has had the opportunity to review this Warrant, the exhibits and schedules attached hereto and the transactions contemplated by this Warrant with its own legal counsel. The Holder is not relying on any statements or representations of the Company or
its agents for legal advice with respect to this investment or the transactions contemplated by this Warrant. 

(l)    Tax Advisors. The Holder has reviewed with its own tax advisors the U.S.
federal, state and local and non-U.S. tax consequences of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on any such advisors and not on any statements or representations of
the Company or any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment and the transactions contemplated by this Warrant.

 12.    Company Representations and Covenants. 

(a)    Capitalization. The Company hereby represents and warrants that, as of
the Original Issue Date, the number of outstanding Shares (assuming the exercise and conversion, as the case may be, of all outstanding options, warrants and shares of the Company’s Preferred Stock) is 18,459,779 shares. 

(b)    Reservation of Shares. Prior to the expiration of this Warrant, the
Company shall at all times reserve and keep available out of its authorized but unissued common stock, solely for the purpose of issuance upon the exercise of this Warrant, the maximum number of Shares issuable upon the exercise of this Warrant, and
the par value per Share shall at all times be less than or equal to the applicable Exercise Price. The Company shall not increase the par value of any Shares receivable upon the exercise of this Warrant above the Exercise Price then in effect, and
shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Shares upon the exercise of this Warrant. 
  
 [***] Information has been omitted and filed separately with the Securities and Exchange Commission.
Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 9 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 13.    Miscellaneous.

 (a)    Amendments. Except as expressly provided herein, neither this
Warrant nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Warrant and signed by the Company and the Holder. 

(b)    Waivers. No waiver of any single breach or default shall be deemed a waiver of
any other breach or default theretofore or thereafter occurring. 
 (c)    Notices.
All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to the Holder) or otherwise delivered by
hand, messenger or courier service addressed: 
 (i)    if to the Holder, to the Holder at
the Holder’s address, facsimile number or electronic mail address as shown in the Company’s records, as may be updated in accordance with the provisions hereof, or until any such Holder so furnishes an address, facsimile number or
electronic mail address to the Company, then to and at the address, facsimile number or electronic mail address of the last holder of this Warrant for which the Company has contact information in its records, with a copy (which shall not constitute
notice) to General Counsel, Towers Watson, 901 North Glebe Road, Arlington, VA 22203; or 

(ii)    if to the Company, to the attention of the President or Chief Financial Officer of the
Company at the Company’s address as shown on the signature page hereto, or at such other current address as the Company shall have furnished to the Holder, with a copy (which shall not constitute notice) to Jon Avina, Wilson Sonsini
Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304. 
 Each such notice or other
communication shall for all purposes of this Warrant be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight
prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for
the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant
electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. 

(d)    Governing Law. This Warrant and all actions arising out of or in connection with
this Warrant shall be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions of the State of California, or of any other state. 

(e)    Jurisdiction and Venue. Each of the Holder and the Company irrevocably consents
to the exclusive jurisdiction and venue of any court within San Mateo County, State of California, in connection with any matter based upon or arising out of this Warrant or the matters contemplated herein, and agrees that process may be served upon
them in any manner authorized by the laws of the State of California for such persons. 

(f)    Titles and Subtitles. The titles and subtitles used in this Warrant are used for
convenience only and are not to be considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits
attached hereto. 
  
 [***] Information has been
omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 10 -

 Confidential Treatment Requested by Extend Health, Inc. 

 

(g)    Severability. If any provision of this Warrant becomes or is declared by a court
of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Warrant, and such illegal, unenforceable or void provision shall be
replaced with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of this Warrant shall be enforceable in accordance
with its terms. 
 (h)    Waiver of Jury Trial. EACH OF THE HOLDER AND THE
COMPANY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS WARRANT. If the waiver of jury
trial set forth in this paragraph is not enforceable, then any claim or cause of action arising out of or relating to this Warrant shall be settled by judicial reference pursuant to California Code of Civil Procedure Section 638 et seq.
before a referee sitting without a jury, such referee to be mutually acceptable to the parties or, if no agreement is reached, by a referee appointed by the Presiding Judge of the California Superior Court for San Mateo County. This paragraph shall
not restrict the Holder or the Company from exercising remedies under the Uniform Commercial Code or from exercising pre-judgment remedies under applicable law. 

(i)    California Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE
SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS
UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING
OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
 (j)    Rights and Obligations Survive
Exercise of the Warrant. Except as otherwise provided herein, the rights and obligations of the Company and the Holder under this Warrant shall survive exercise of this Warrant. 

(k)    Entire Agreement. Except as expressly set forth herein, this Warrant (including
the exhibits attached hereto) constitutes the entire agreement and understanding of the Company and the Holder with respect to the subject matter hereof and supersede all prior agreements and understandings relating to the subject matter hereof.

 (signature page follows) 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 11 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 The Company and the Holder sign this Warrant
as of the date stated on the first page. 
  

			
	 EXTEND HEALTH, INC.

		
	 By:
	 	 /s/ Bryce Williams

 
			
		
	 Name:
	 	 Bryce Williams

		
	 Title:
	 	 President & CEO

	
	 Address:

	
	 2929 Campus Drive, Suite 400
 San Mateo, California 94403

  

			
	 AGREED AND ACKNOWLEDGED,

 
 TOWERS WATSON PENNSYLVANIA
INC.

		
	 By:
	 	 /s/ Gordon L. Gould

			
		
	 Name:
	 	 Gordon L. Gould

		
	 Title:
	 	 Managing Director, Strategy & Corporate Development

	
	 Address:

	
	 1500 Market Street
 Centre Square East
 Philadelphia, Pennsylvania 19102

 
 Fax number: (215) 246-4463

 
 Email address:

 (Signature Page to Warrant to Purchase Shares of Common Stock of Extend Health,
Inc.) 
  
 [***]
Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

 Confidential Treatment Requested by Extend Health, Inc. 

 
 SCHEDULE 1 

Sales Targets Achievement 
 This Warrant shall be exercisable, in whole or in part, for the number of Shares set forth in one of the “Tiers” in the chart below (each, a “Tier”), as appropriate. The
applicable Tier will be based upon the aggregate number of Eligible Enrollments (as defined in the Referral Agreement) credited to Holder for Accepted Referrals earned as of the Determination Date pursuant to the Referral Agreement. 

 

																					
	 	  	Tier 1	 	  	Tier 2	 	  	Tier 3	 	  	Tier 4	 	  	Tier 5	 
	 Eligible Enrollments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Shares of Common Stock earned
	  	 	94,801	  	  	 	189,602	  	  	 	284,403	  	  	 	379,204	  	  	 	474,005	  
						
	 	  	Tier 6	 	  	Tier 7	 	  	Tier 8	 	  	Tier 9	 	  	Tier 10	 
	 Eligible Enrollments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Shares of Common Stock earned
	  	 	568,806	  	  	 	663,607	  	  	 	758,408	  	  	 	853,209	  	  	 	948,011	  

  
 [***] Information has been
omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 Schedule I

 Confidential Treatment Requested by Extend Health, Inc. 

 
 EXHIBIT A 

NOTICE OF EXERCISE 
 TO:                    EXTEND HEALTH, INC. (the “Company”)

 Attention:        President 

 

	 (1)
	 Exercise. The undersigned elects to purchase the following pursuant to the terms of the attached warrant: 

 

					
	 Number of shares:
	  	 	  	
			
	 Type of security:
	  	 	  	

  

	 (2)
	 Method of Exercise. The undersigned elects to exercise the attached warrant pursuant to: 

 

					
	  ̈
	  	 A cash payment, and tenders herewith payment of the purchase price for such shares in full, together with all applicable transfer taxes, if
any.

  

	 (3)
	 Stock Certificate. Please issue a certificate or certificates representing the shares in the name of: 

 

							
		 	   ̈           The undersigned
	  		  	
				
		 	   ̈           Other—Name:
	  	 	  	
				
		 	
                             
Address:
	  	 	  	
				
		 		  	 	  	

  

	 (4)
	 Unexercised Portion of the Warrant. Please issue a new warrant for the unexercised portion of the attached warrant in the name of:

  

							
		 	   ̈           The undersigned
	  		  	
				
		 	   ̈           Other—Name:
	  	 	  	
				
		 	
                             
Address:
	  	 	  	
				
		 		  	 	  	
				
		 	   ̈          Not applicable
	  		  	

  

	 (5)
	 Investment Intent. The undersigned represents and warrants that the aforesaid shares are being acquired for investment for its own account,
not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and that the undersigned has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor
does it have any contract, undertaking, agreement or arrangement for the same, and all representations and warranties of the undersigned set forth in Section 11 of the attached warrant are true and correct as of the date hereof.

  

	 (6)
	 Investment Representation Statement and Market Stand-Off Agreement. The undersigned has executed, and delivers herewith, an Investment
Representation Statement and Market Stand-Off Agreement in a form substantially similar to the form attached to the warrant as Exhibit A-1. 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 A-1

 Confidential Treatment Requested by Extend Health, Inc. 

 
  

	 (7)
	 Consent to Receipt of Electronic Notice. Subject to the limitations set forth in Delaware General Corporation Law §232(e), the
undersigned consents to the delivery of any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) electronic mail to the electronic mail
address provided below (or to any other electronic mail address for the undersigned in the Company’s records) or (ii) posting on an electronic network together with separate electronic mail notice to the undersigned of such specific
posting. This consent may be revoked by the undersigned by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law §232. 

 

	
	
	  
	(Print name of the warrant holder)

 
	
	
	  
	(Signature)

 
	
	
	  
	(Name and title of signatory, if applicable)

 
	
	
	  
	(Date)

 
	
	
	  
	(Email address)

 (Signature page to the Notice of Exercise) 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 A-2

 Confidential Treatment Requested by Extend Health, Inc. 

 
 EXHIBIT A-l 

INVESTMENT REPRESENTATION STATEMENT 
 AND 
 MARKET STAND-OFF AGREEMENT 

 

			
	 INVESTOR:
	  	  

		
	 COMPANY:
	  	 EXTEND HEALTH, INC.

		
	 SECURITIES:
	  	 THE WARRANT ISSUED ON AUGUST 15, 2011 (THE “WARRANT”) AND THE SECURITIES ISSUED OR ISSUABLE UPON EXERCISE THEREOF

  

					
	 DATE:
	  	 	  	

 In connection with the purchase or acquisition of the above-listed Securities, the
undersigned Investor represents and warrants to, and agrees with, the Company as follows: 

1.    No Registration. The Investor understands that the Securities have not been, and may not
be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other
things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein or otherwise made pursuant hereto. 

2.    Investment Intent. The Investor is acquiring the Securities for investment for its own
account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. The Investor has no present intention of selling, granting any participation in, or otherwise distributing the Securities, nor
does it have any contract, undertaking, agreement or arrangement for the same. 

3.    Investment Experience. The Investor has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating the merits and risks of its investment in the
Company and protecting its own interests. 
 4.    Speculative Nature of Investment.
The Investor understands and acknowledges that the Company has a limited financial and operating history and that its investment in the Company is highly speculative and involves substantial risks. The Investor can bear the economic risk of its
investment and is able, without impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 

5.    Access to Data. The Investor has had an opportunity to ask questions of officers of the
Company, which questions were answered to its satisfaction. The Investor believes that it has received all the information that it considers necessary or appropriate for deciding whether to acquire the Securities. The Investor understands that any
such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Investor acknowledges that
any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the
assumptions underlying the projections will not materialize or will vary significantly from actual results. 
  

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been
requested with respect to the omitted portions. 

  
 A-1-1

 Confidential Treatment Requested by Extend Health, Inc. 

 
 6.    Accredited
Investor. The Investor is an “accredited investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such
status as may be reasonably requested by the Company. 
 7.    Residency. The
residency of the Investor (or, in the case of a partnership or corporation, such entity’s principal place of business) is correctly set forth on the signature page hereto. 

8.    Restrictions on Resales. The Investor acknowledges that the Securities must be held
indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act, which permit resale of shares
purchased in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not less than a specified
period after a party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s transaction,” a
transaction directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder); and the filing of a Form 144 notice, if applicable. The Investor acknowledges and understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the Investor wishes to sell the
Securities and that, in such event, the Investor may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of Rule 144 have been satisfied. The Investor understands and acknowledges that, in the
event the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Investor understands that, although Rule 144 is
not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a
substantial burden of proof in establishing that an exemption from registration is available for those offers or sales and that those persons and the brokers who participate in the transactions do so at their own risk. 

9.    No Public Market. The Holder understands and acknowledges that no public market now
exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 

10.    Brokers and Finders. The Investor has not engaged any brokers, finders or agents in
connection with the Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Investor, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with the Securities. 
 11.    Legal Counsel. The Investor has
had the opportunity to review the Warrant, the exhibits and schedules attached thereto and the transactions contemplated by the Warrant with its own legal counsel. The Investor is not relying on any statements or representations of the Company or
its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant. 

12.    Tax Advisors. The Investor has reviewed with its own tax advisors the U.S. federal,
state and local and non-U.S. tax consequences of this investment and the transactions contemplated by the Warrant. With respect to such matters, the Investor relies solely on such advisors and not on any statements or representations of the Company
or any of its agents, written or oral. The Investor understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by the Warrant. 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 A-1-2

 Confidential Treatment Requested by Extend Health, Inc. 

 
 13.    Market
Stand-off. The Investor agrees that the Investor is subject to Section 10 of the Warrant. 
 (signature page
follows) 
  
 [***] Information has been
omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 A-1-3

 Confidential Treatment Requested by Extend Health, Inc. 

 
 The Investor is signing this Investment
Representation Statement and Market Stand-Off Agreement on the date first written above. 
  

	
	 INVESTOR

	
	  
	(Print name of the investor)

  

	
	  
	(Signature)

 
	
	
	  
	(Name and title of signatory, if applicable)

 
	
	
	  
	(Street address)

 
	
	
	  
	(City, state and ZIP)

  
 [***] Information has
been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 A-1-4

 Confidential Treatment Requested by Extend Health, Inc. 

 
 EXHIBIT B 

ASSIGNMENT FORM 
  

			
	 ASSIGNOR:
	  	  

		
	 COMPANY:
	  	 EXTEND HEALTH, INC.

		
	 WARRANT:
	  	 THE WARRANT TO PURCHASE SHARES OF COMMON STOCK ISSUED ON AUGUST 15, 2011 (THE “WARRANT”)

  

					
	 DATE:
	  	 	  	

  

	 (1)
	 Assignment. The undersigned registered holder of the Warrant (“Assignor”) assigns and transfers to the assignee named
below (“Assignee”) all of the rights of Assignor under the Warrant, with respect to the number of shares set forth below: 

  

			
	 Name of Assignee:
	  	 
		
	 Address of Assignee:
	  	 
		
		  	 

  

					
	                 Number of Shares Assigned:
	  	 

 and does irrevocably constitute and appoint ______________________ as attorney to make
such transfer on the books of Extend Health, Inc., maintained for the purpose, with full power of substitution in the premises. 
  

	 (2)
	 Obligations of Assignee. Assignee agrees to take and hold the Warrant and any shares of stock to be issued upon exercise of the rights
thereunder (the “Securities”) subject to, and to be bound by, the terms and conditions set forth in the Warrant to the same extent as if Assignee were the original holder thereof. 

 

	 (3)
	 Investment Intent. Assignee represents and warrants that the Securities are being acquired for investment for its own account, not as a
nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and that Assignee has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any
contract, undertaking, agreement or arrangement for the same, and all representations and warranties set forth in Section 11 of the Warrant are true and correct as to Assignee as of the date hereof. 

 

	 (4)
	 Investment Representation Statement and Market Stand-Off Agreement. Assignee has executed, and delivers herewith, an Investment
Representation Statement and Market Stand-Off Agreement in a form substantially similar to the form attached to the Warrant as Exhibit A-1. 

 
 [***] Information has been omitted and filed separately with
the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 1 -

 Confidential Treatment Requested by Extend Health, Inc. 

 
 Assignor and Assignee are signing this
Assignment Form on the date first set forth above. 
  

					
	 ASSIGNOR
	 		 	 ASSIGNEE

			
	  	 		 	  
	(Print name of Assignor)	 		 	(Print name of Assignee)
			
	  	 		 	  
	(Signature of Assignor)	 		 	(Signature of Assignee)
			
	  	 		 	  
	(Print name of signatory, if applicable)	 		 	(Print name of signatory, if applicable)
			
	  	 		 	  
	(Print title of signatory, if applicable)	 		 	(Print title of signatory, if applicable)

  

					
	 Address:
	 		 	 Address:

			
	  	 		 	  
			
	  	 		 	  

  
 [***] Information has been
omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

  
 - 2 -Employment Agreement

 Exhibit 10.5 
 EXTEND HEALTH, INC. 
 BRYCE A. WILLIAMS EMPLOYMENT AGREEMENT

 This Agreement is entered into as of July 27, 2007 (the “Effective Date”) by and between EXTEND
HEALTH, INC. (the “Company”), and BRYCE A. WILLIAMS (“Executive”). 

1.    Duties and Scope of Employment. 
 (a)    Position and Duties. As of the Effective Date, Executive will serve as President and Chief Executive Officer of the Company. Executive will render such business and
professional services in the performance of his duties, consistent with Executive’s position within the Company, as shall reasonably be assigned to him by the Company’s Board of Directors (the “Board”). The period of
Executive’s employment under this Agreement is referred to herein as the “Employment Term.” 

(b)    Board Membership. During the Employment Term, Executive will serve as a member and Chairman of the
Board, subject to any required Board and/or stockholder approval. 
 (c)    Obligations. During the
Employment Term, Executive will perform his duties faithfully and to the best of his ability and will devote his full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any
other employment, occupation or consulting activity for any direct or indirect remuneration without the prior approval of the Board. 
 2.    At-Will Employment. The parties agree that Executive’s employment with the Company will be “at-will” employment and may be terminated at any time with or
without cause or notice. Executive understands and agrees that neither his job performance nor promotions, commendations, bonuses or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension,
by implication or otherwise, of his employment with the Company. 
 3.    Compensation. 

(a)    Base Salary. During the Employment Term, the Company will pay Executive as compensation for his
services a base salary at the annualized rate of Two Hundred Ninety-Five Thousand Dollars ($295,000.00) (the “Base Salary”). The Base Salary will be paid periodically in accordance with the Company’s normal payroll practices and be
subject to the usual, required withholding. 
 (b)    Bonus. During the Employment Term, Executive
will be eligible to receive a quarterly discretionary performance bonus based upon performance measurement criteria to be determined by the Board of Directors. The Board will determine whether these performance goals have been met. This bonus
payment will be earned only on the date of payment, and Executive must be employed by the Company on the date of payment. 

 (c)    Stock Option. Executive has been granted certain stock
options: (i) a stock option to purchase 363,546 shares of Company common stock granted on July 29, 2005 with a vesting commencement date of July 29, 2005; and (ii) a stock option to purchase 724,493 shares of Company common stock
granted on August 17, 2007 with a vesting commencement date of July 27, 2007 (each, an “Option” and together, the “Options”). The Options are subject to the terms, definitions and provisions of the stock option plan
under which they were granted (the Company’s 2004 Equity Incentive Plan or 2007 Equity Incentive Plan, as applicable) (each, an “Option Plan” and together, the “Option Plans”) and the stock option agreements by and between
Executive and the Company relating to each Option (the “Option Agreements”), both of which documents are incorporated herein by reference. 
 4.    Employee Benefits. During the Employment Term, Executive will be entitled to participate in the employee benefit plans currently and hereafter maintained by the Company of
general applicability to other senior executives of the Company, including, without limitation, the Company’s group medical, dental, vision, disability, life insurance, and flexible-spending account plans. The Company reserves the right to
cancel or change the benefit plans and programs it offers to its employees at any time. 

5.    Vacation. Executive will be entitled to paid vacation of twelve (12) days per year in accordance
with the Company’s vacation policy, with the timing and duration of specific vacations mutually and reasonably agreed to by the parties hereto. 
 6.    Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in the furtherance of or in connection with the
performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time. 
 7.    Termination of Employment. In the event Executive’s employment with the Company terminates for any reason, Executive will be entitled to any (a) unpaid Base
Salary accrued up to the effective date of termination; (b) pay for accrued but unused vacation; (c) benefits or compensation as provided under the terms of any employee benefit and compensation agreements or plans applicable to Executive
(d) unreimbursed business expenses required to be reimbursed to Executive, and (e) rights to indemnification Executive may have under the Company’s Articles of Incorporation, Bylaws, the Agreement, or separate indemnification
agreement, as applicable. In addition, depending on the reason for termination, Executive may be entitled to the amounts and benefits specified in Sections 8 and/or 9. 
 8.    Severance. 

(a)    Involuntary Termination. If Executive’s employment with the Company is
terminated by the Company without “Cause” (as defined herein) or the Executive resigns for Good Reason, and Executive signs and does not revoke a standard release of claims with the Company, within two and one-half (2 1/2) months following the end of the calendar year in which the
Executive’s 

  
 -2-

 
termination of employment occurs then, subject to Section 13, Executive shall be entitled to continued payments of severance pay (less applicable withholding taxes) at a rate equal to his
then-current Base Salary rate for a period of six (6) months from the date of termination, payable periodically according to the Company’s normal payroll practices. 
 (b)    Voluntary Termination; Termination by reason of Death or Disability; Termination for Cause. If Executive’s employment with the Company terminates voluntarily by
Executive without Good Reason, terminates as a result of Executive’s death or Disability, or is terminated by the Company for Cause, then (i) all vesting of the Options and any additional Company stock options or other equity awards
granted to Executive will terminate immediately and all payments of compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and (ii) Executive will only be eligible for severance
benefits in accordance with the Company’s established policies as then in effect. Except as may be provided by Section 9, if Executive’s employment with the Company terminates for any reason, all vesting of the Options and any
additional Company stock options and other equity awards granted to Executive will terminate immediately. 

9.    Change of Control Benefits. If within twelve (12) months following a “Change of Control”
(as defined below) (i) Executive’s employment with the Company is terminated by the Company without Cause, or (ii) the Executive resigns for Good Reason, then in addition to any severance benefits to which Executive may be entitled
pursuant to Section 8(a), 100% of the shares subject to the then-outstanding Options and any additional then-outstanding stock options granted to Executive to purchase Company common stock (each, an “Additional Option”) shall vest and
become exercisable. Thereafter, each Option will continue to be subject to the terms, definitions and provisions of the Option Plan under which it was granted and applicable Option Agreement and each Additional Option, if any, will continue to be
subject to the terms, definitions and provisions of the plan under which it was granted and the option agreement between Executive and the Company governing such stock option (together, the “Option Documents”), each of which is
incorporated herein by reference. The Option Agreements are amended by this Section 9; to the extent not amended by this Agreement, the Option Agreements remain in full force and effect. 

10.    Section 409A. Notwithstanding anything to the contrary in this Agreement, if Employee is a
“specified employee” within the meaning of Section 409A at the time of Employee’s termination (other than due to death), then only that portion of the severance payable to Employee pursuant to this Agreement, if any, and any
other severance payments or separation benefits which may be considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”), which (when considered together) do not exceed the
“Section 409A Limit” (as defined below) may be made within the first six (6) months following. Employee’s termination of employment in accordance with the payment schedule applicable to each payment or benefit. Any portion
of the Deferred Compensation Separation Benefits in excess of the Section 409A Limit otherwise due to Employee on or within the six (6) month period following Employee’s termination will accrue during such six (6) month period
and will become payable in a lump sum payment on the date six (6) months and one (1) day following the date of Employee’s termination of employment. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in
accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following his termination but 

  
 -3-

 
prior to the six month anniversary of his date of termination, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable
after the date of Executive’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. It is the intent of this Agreement to comply with the
requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply.

 11.    Definitions. 
 (a)    Cause. For purposes of this Agreement, “Cause” is defined as (i) an act of dishonesty made by Executive in connection with Executive’s
responsibilities as an employee, (ii) Executive’s conviction of, or plea of nolo contendere to, a felony, (iii) Executive’s gross misconduct, or (iv) Executive’s continued substantial violations of his employment
duties after Executive has received a written demand for performance from the Company which specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed his duties. Termination by reason of
the Executive’s death or Disability shall not be deemed a termination without Cause for purposes of this Agreement. 

(b)    Change of Control. For purposes of this Agreement, “Change of Control” of the Company is
defined as: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), other than the Company, a subsidiary of the Company or a Company employee benefit plan, including
any trustee of such plan acting as trustee, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power
represented by the Company’s then outstanding voting securities; or (ii) a change in the composition of the Board occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors.
“Incumbent Directors” will mean directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the
Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or
(iii) the date of the consummation of a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or resulting
entity, including any parent or holding company) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or
(iv) the stockholders of the Company approve a plan of complete liquidation of the Company; or (v) the date of the consummation of the sale or disposition by the Company of all or substantially all the Company’s assets.
Notwithstanding the foregoing, a transaction shall not constitute a Change of Control if: (i) its sole purpose is to change the state of the Company’s incorporation, or (ii) its sole purpose is to create a holding company that shall
be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. 

  
 -4-

 (c)    Code. For purposes of this Agreement, “Code”
means the Internal Revenue Code of 1986, as amended. 
 (d)    Disability. For purposes of this
Agreement, “Disability” means the inability of Executive, due to a physical or mental impairment, to perform the essential functions of Executive’s position, with or without reasonable accommodation, for a period of ninety
(90) days. Whether Executive is disabled will be determined by the Company based on evidence provided by one or more physicians selected by the Company. 
 (e)    Section 409A. For purposes of this Agreement, “Section 409A” means Section 409A of the Code, as it has been or may be amended from time to time,
and any temporary, proposed or final regulations and guidance promulgated thereunder. 

(f)    Section 409A Limit. For purposes of this Agreement, “Section 409A Limit” means the
lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Company’s taxable year preceding the Company’s taxable year of Executive’s termination of
employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant
to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated. 

(g)    Good Reason. For purposes of this Agreement, “Good Reason” shall mean: (a) a material
diminution of Executive’s then current Base Salary; (b) a material change in the geographic location at which Executive must perform his services; provided that in no instance will the relocation of Executive to a facility or a location of
50 miles or less from Executive’s then current office location be deemed material for purposes of this Agreement; or (c) there is a material reduction in Executive’s overall title, responsibilities or authority, or scope of
duties, except that the failure of the Company to obtain the same job title for the Executive following a Change in Control as Executive had prior to the Change in Control where the Executive retains a position of materially similar or greater
overall scope and responsibility within the acquiring company, taking into appropriate consideration that a nominally lower hierarchical role in a larger company may involve similar or greater scope and responsibility than a nominally higher role in
the hierarchy of a smaller company, will not constitute “Good Reason” for purposes of this Agreement. It is understood, however, that before Executive may resign for Good Reason, (A) Executive must provide the Company with written
notice within forty-five (45) days of the event that Executive believes constitutes “Good Reason” specifically identifying the acts or omissions constituting the grounds for Good Reason and (B) the Company must have an
opportunity within thirty (30) days following delivery of such notice to cure the Good Reason condition. In no instance will a resignation by Executive be deemed to be for Good Reason if it is made more than twenty four (24) months
following the initial occurrence of any of the events that otherwise would constitute Good Reason hereunder. 

12.    Confidential Information. Executive agrees to enter into the Company’s standard At-Will
Employment, Confidential Information, Invention Assignment and Arbitration Agreement attached as Exhibit A (the “Confidentiality Agreement”) upon commencing employment hereunder. 

  
 -5-

 13.    Conditional Nature of Severance
Payments. The receipt of any severance or other benefits pursuant to Section 8 will be subject to Executive signing and not revoking a separation agreement and release of claims in a form acceptable to the Company within two and one-half (2 1/2) months following the end of the calendar year
in which the Executive’s termination of employment occurs. No severance or other benefits will be paid or provided until the separation agreement and release of claims becomes effective. Executive further agrees and acknowledges that
Executive’s right to receive the severance payments set forth in Section 8 (to the extent Executive is otherwise entitled to such payments) will be conditioned upon Executive not directly or indirectly engaging in (whether as an employee,
consultant, agent, proprietor, principal, partner, stockholder, corporate officer, director or otherwise), nor having any ownership interest in or participating in the financing, operation, management or control of any person, firm, corporation or
business that directly competes with the Company (or any parent or subsidiary of the Company) or is a customer of the Company (or any parent or subsidiary of the Company), in each case during the six (6) month period in which Employee is
eligible to receive severance payments. Upon any breach of this section, all severance payments pursuant to Section 8 of this Agreement will immediately cease. 
 14.    Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon Executive’s
death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm,
corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form
of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive’s right to
compensation or other benefits will be null and void. 
 15.    Notices. All notices, requests,
demands and other communications called for hereunder shall be in writing and shall be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight
service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties
may later designate in writing: 
 If to the Company: 
 Extend Health, Inc.  
 330 Primrose Road, Suite 610

 Burlingame, CA. 94010  
 Attn: Board of Directors 
 If to Executive: 

at the last residential address known by the Company. 

  
 -6-

 16.    Severability. In the event that any provision hereof
becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. 
 17.    Arbitration. 

(a)    General. In consideration of Executive’s employment with the Company, its promise to arbitrate all
employment-related disputes, and Executive’s receipt of the compensation, pay raises, and other benefits paid to Executive by the Company, at present and in the future, Executive agrees that any and all controversies, claims, or disputes with
anyone (including the Company and any employee, officer, director, shareholder, or benefit plan of the company, in their capacity as such or otherwise), whether brought on an individual, group, or class basis, arising out of relating to, or
resulting from Executive’s employment with the Company or the termination of Executive’s employment with the Company, including any breach of this agreement, shall be subject to binding arbitration under the arbitration rules set forth in
California Code of Civil procedure section 1280 through 1294.2, including section 1283.05 (the “Rules”), and pursuant to California law. Disputes that Executive agrees to arbitrate, and thereby agrees to waive any right to a trial by jury,
include any statutory claims under local, state, or federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans With Disabilities Act of 1990, the Age Discrimination in Employment Act of
1967, the Older Workers Benefit Protection Act, the Sarbanes-Oxley Act, the Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act, the Family and Medical Leave Act, the California Family Rights Act, the
California Labor Code, claims of harassment, discrimination, and wrongful termination, and any statutory or common law claims. Executive further understands that this agreement to arbitrate also applies to any disputes that the Company may have with
Executive. 
 (b)    Procedure. Executive agrees that any arbitration will be administered by
Judicial Arbitration & Mediation Services, Inc. (“JAMS”), pursuant to its Employment Arbitration Rules & Procedures (the “JAMS RULES”). Executive agrees that the arbitrator shall have the power to decide any
motions brought by any party to the arbitration, including motions for summary judgment and/or adjudication, motions to dismiss and demurrers, and motions for class certification, prior to any arbitration hearing. Executive also agrees that the
arbitrator shall have the power to award any remedies available under applicable law, and that the arbitrator shall award attorneys’ fees and costs to the prevailing party, except as prohibited by law. Executive understands that the Company
will pay for any administrative or hearing fees charged by the arbitrator or JAMS except that Executive shall pay any filing fees associated with any arbitration that Executive initiates, but only so much of the filing fees as Executive would have
instead paid had Executive filed a complaint in a court of law. Executive agrees that the arbitrator shall administer and conduct any arbitration in accordance with California law, including the California Code of Civil Procedure, and that the
arbitrator shall apply substantive and procedural California law to any dispute or claim, without reference to rules of conflict of law. To the extent that the JAMS RULES conflict with California law, California law shall take precedence. Executive
agrees that the decision of the arbitrator shall be in writing. Executive agrees that any arbitration under this agreement shall be conducted in Santa Clara County, California. 

  
 -7-

 (c)    Remedy. Except as provided by the Rules and this
agreement, arbitration shall be the sole, exclusive, and final remedy for any dispute between Executive and the Company. Accordingly, except as provided for by the rules and this agreement, neither Executive nor the Company will be permitted to
pursue court action regarding claims that are subject to arbitration. Notwithstanding, the arbitrator will not have the authority to disregard or refuse to enforce any lawful Company policy, and the arbitrator shall not order or require the Company
to adopt a policy not otherwise required by law. Nothing in this agreement or in this provision is intended to waive the provisional relief remedies available under the Rules. 
 (d)    Administrative Relief. Executive understands that this Agreement does not prohibit Executive from pursuing an administrative claim with a local, state, or federal
administrative body such as the Department of Fair Employment and Housing, the Equal Employment Opportunity Commission, the National Labor Relations Board, or the Workers’ Compensation Board. This Agreement does, however, preclude Executive
from pursuing court action regarding any such claim. 
 (e)    Voluntary Nature of Agreement.
Executive acknowledges and agrees that Executive is executing this Agreement voluntarily and without any duress or undue influence by the Company or anyone else. Executive further acknowledges and agrees that Executive has carefully read this
agreement and that Executive has asked any questions needed for Executive to understand the terms, consequences and binding effect of this agreement and fully understand it, including that Executive is waiving executive’s right to a jury trial.
Finally, Executive agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive’s choice before signing this Agreement. 
 18.    Integration. This Agreement, together with the Option Documents and the Confidentiality Agreement, represent the entire agreement and understanding between the parties as
to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions
which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition under Section 409A prior to actual payment to Executive. No waiver, alteration, or modification of any of the provisions of this
Agreement will be binding unless in writing and signed by duly authorized representatives of the parties hereto. 

19.    Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of
applicable taxes. 
 20.    Governing Law. This Agreement will be governed by the laws of the State
of California (with the exception of its conflict of laws provisions). 
 21.    Acknowledgment.
Executive acknowledges that he has had the opportunity to discuss this matter with and obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is
knowingly and voluntarily entering into this Agreement. 

  
 -8-

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the
Company by their duly authorized officers, as of the day and year first above written. 
 COMPANY: 

 

					
	EXTEND HEALTH, INC.	 		 	
			
	By: /s/ Bryce A.
Williams                                        
                    	 		 	Date: 12/26/2007                          
                                         
     
			
	Title: President &
CEO                                         
                       	 		 	

  

					
	 EXECUTIVE:
	 		 	
			
	/s/Bryce A.
Williams                                        
                            	 		 	Date: 12/26/2007                          
                                         
     
	Bryce A. Williams	 		 	

  
 -9-

 EXHIBIT A 
 EXTEND HEALTH, INC. 
 AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION,

 INVENTION ASSIGNMENT, 
 AND ARBITRATION AGREEMENT 
 As a condition of my employment with Extend
Health, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, I agree
to the following: 
 1.    At-Will Employment. 

I UNDERSTAND AND ACKNOWLEDGE THAT MY EMPLOYMENT WITH THE COMPANY IS FOR AN UNSPECIFIED DURATION AND CONSTITUTES “AT-WILL”
EMPLOYMENT. I ALSO UNDERSTAND THAT ANY REPRESENTATION TO THE CONTRARY IS UNAUTHORIZED AND NOT VALID UNLESS IN WRITING AND SIGNED BY THE PRESIDENT OF THE COMPANY. ACCORDINGLY, I ACKNOWLEDGE THAT MY EMPLOYMENT RELATIONSHIP MAY BE TERMINATED AT ANY
TIME, WITH OR WITHOUT GOOD CAUSE OR FOR ANY OR NO CAUSE, AT MY OPTION OR AT THE OPTION OF THE COMPANY, WITH OR WITHOUT NOTICE. 

2.    Confidential Information. 
 (a)    Company Information. I agree at all times during my employment with the Company and thereafter, to hold in the strictest confidence, and not to use, except for the
benefit of the Company, or to disclose to any person, firm or corporation without written authorization of the President or the Board of Directors of the Company, any Company Confidential Information. I understand that my unauthorized use or
disclosure of Company Confidential Information during my employment may lead to disciplinary action, up to and including immediate termination and legal action by the Company. I understand that “Company Confidential Information”
means any nonpublic information that relates to the actual or anticipated business, research or development of the Company, or to the Company’s technical data, trade secrets, or know-how, including, but not limited to, research, product plans,
or other information regarding the Company’s products or services and markets therefor, customer lists and customers (including, but not limited to, customers of the Company on which I called or with which I may become acquainted during the
term of my employment), software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and other business information; provided, however, Company
Confidential Information does not include any of the foregoing items to the extent the same have become publicly known and made generally available through no wrongful act of mine or of others. 

 (b)    Former Employer Information. I agree that during my
employment with the Company, I will not improperly use, disclose, or induce the Company to use any proprietary information or trade secrets of any former or concurrent employer or other person or entity. I further agree that I will not bring onto
the premises of the Company or transfer onto the Company’s technology systems any unpublished document, proprietary information, or trade secrets belonging to any such employer, person, or entity unless consented to in writing by both the
Company and such employer, person, or entity. 
 (c)    Third-Party Information. I recognize that the
Company may have received and in the future may receive from third parties associated with the Company, e.g., the Company’s customers, suppliers, licensors, licensees, partners, or collaborators (“Associated Third Parties”),
their confidential or proprietary information (“Associated Third Party Confidential Information”). By way of example, Associated Third Party Confidential Information may include the habits or practices of Associated Third Parties,
the technology of Associated Third Parties, requirements of Associated Third Parties, and information related to the business conducted between the Company and such Associated Third Parties. I agree at all times during my employment with the Company
and thereafter to hold in the strictest confidence, and not to use or to disclose to any person, firm, or corporation, any Associated Third Party Confidential Information, except as necessary in carrying out my work for the Company consistent with
the Company’s agreement with such Associated Third Parties. I understand that my unauthorized use or disclosure of Associated Third Party Confidential Information during my employment will lead to disciplinary action, up to and including
immediate termination and legal action by the Company. 
 3.    Inventions. 

(a)    Inventions Retained and Licensed. I have attached hereto as Exhibit A, a list describing
all inventions, discoveries, original works of authorship, developments, improvements, and trade secrets that were conceived in whole or in part by me prior to my employment with the Company and to which I have any right, title, or interest, which
are subject to California Labor Code Section 2870 (attached hereto as Exhibit B), and which relate to the Company’s proposed business, products, or research and development (“Prior Inventions”); or, if no such
list is attached, I represent and warrant that there are no such Prior Inventions. Furthermore, I represent and warrant that the inclusion of any Prior Inventions on Exhibit A of this Agreement will not materially affect my ability to
perform all obligations under this Agreement. If, in the course of my employment with the Company, I incorporate into or use in connection with any product, process, service, technology, or other work by or on behalf of the Company any Prior
Invention, I hereby grant to the Company a non-exclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license, with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, and sell
such Prior Invention as part of or in connection with such product, process, service, technology, or other work, and to practice any method related thereto. 
 (b)    Assignment of Inventions. I agree that I will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and
hereby assign to the Company, or its designee, all my right, title, and interest in and to any and all 

  
 -2-

 
inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas, trademarks, or trade secrets, whether or not patentable or registrable under patent,
copyright, or similar laws, which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company (including during my
off-duty hours), or with the use of Company’s equipment, supplies, facilities, or Company Confidential Information, except as provided in Section 3.(e) below (collectively referred to as “inventions”). I further
acknowledge that all original works of authorship that are made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and that are protectable by copyright are “works made for
hire,” as that term is defined in the United States Copyright Act. I understand and agree that the decision whether or not to commercialize or market any Inventions is within the Company’s sole discretion and for the Company’s sole
benefit, and that no royalty or other consideration will be due to me as a result of the Company’s efforts to commercialize or market any such Inventions. 
 (c)    Maintenance of Records. I agree to keep and maintain adequate, current, accurate, and authentic written records of all Inventions made by me (solely or jointly with
others) during the term of my employment with the Company. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any other format that may be specified by the Company. The records are and will be available to
and remain the sole property of the Company at all times. 
 (d)    Patent and Copyright
Registrations. I agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Inventions and any rights relating thereto in any and all countries, including the
disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments, and all other instruments that the Company shall deem proper or necessary in order to apply
for, register, obtain, maintain, defend, and enforce such rights, and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to such Inventions and any rights
relating thereto, and testifying in a suit or other proceeding relating to such Inventions and any rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is in my power to do so, any such instrument
or papers shall continue after the termination of this Agreement. If the Company is unable because of my mental or physical incapacity or for any other reason to secure my signature with respect to any Inventions, including, without limitation, to
apply for or to pursue any application for any United States or foreign patents or copyright registrations covering such Inventions, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent
and attorney in fact, to act for and in my behalf and stead, to execute and file any papers and oaths, and to do all other lawfully permitted acts with respect to such Inventions with the same legal force and effect as if executed by me. 

(e)    Exception to Assignments. I understand that the provisions of this Agreement requiring assignment of
Inventions to the Company do not apply to any invention that qualifies fully under the provisions of California Labor Code Section 2870 (attached hereto as Exhibit B). I will advise the Company promptly in writing of any inventions
that I believe meet the criteria in California Labor Code Section 2870 and are not otherwise disclosed on Exhibit A. 

  
 -3-

 4.    Conflicting Employment. 

(a)    Current Obligations. I agree that during the term of my employment with the Company, I will not engage
in or undertake any other employment, occupation, consulting relationship, or commitment that is directly related to the business in which the Company is now involved or becomes involved or has plans to become involved, nor will I engage in any
other activities that conflict with my obligations to the Company. 
 (b)    Prior Relationships.
Without limiting Section 4.A, I represent that I have no other agreements, relationships, or commitments to any other person or entity that conflict with my obligations to the Company under this Agreement or my ability to become employed and
perform the services for which I am being hired by the Company. I further agree that if I have signed a confidentiality agreement or similar type of agreement with any former employer or other entity, I will comply with the terms of any such
agreement to the extent that its terms are lawful under applicable law. I represent and warrant that after undertaking a careful search (including searches of my computers, cell phones, electronic devices, and documents), I have returned all
property and confidential information belonging to all prior employers. Moreover, I agree to fully indemnify the Company, its directors, officers, agents, employees, investors, shareholders, administrators, affiliates, divisions, subsidiaries,
predecessor and successor corporations, and assigns for all verdicts, judgments, settlements, and other losses incurred by any of them resulting from my breach of my obligations under any agreement to which I am a party or obligation to which I am
bound, as well as any reasonable attorneys’ fees and costs if the plaintiff is the prevailing party in such an action. 

5.    Returning Company Documents. Upon separation from employment with the Company or on demand by the
Company during my employment, I will immediately deliver to the Company, and will not keep in my possession, recreate, or deliver to anyone else, any and all Company property, including, but not limited to, Company Confidential Information,
Associated Third Party Confidential Information, as well as all devices and equipment belonging to the Company (including computers, handheld electronic devices, telephone equipment, and other electronic devices), Company credit cards, records,
data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, photographs, charts, any other documents and property, and reproductions of any and all of the aforementioned items
that were developed by me pursuant to my employment with the Company, obtained by me in connection with my employment with the Company, or otherwise belonging to the Company, its successors, or assigns, including, without limitation, those records
maintained pursuant to Section 3(c). I also consent to an exit interview to confirm my compliance with this Section 5. 
 6.    Termination Certification. Upon separation from employment with the Company, I agree to immediately sign and deliver to the Company the “Termination
Certification” attached hereto as Exhibit C. I also agree to keep the Company advised of my home and business address for a period of three (3) years after termination of my employment with the Company, so that the Company can
contact me regarding my continuing obligations provided by this Agreement. 

  
 -4-

 7.    Notification of New Employer. In the event that I leave the
employ of the Company, I hereby grant consent to notification by the Company to my new employer about my obligations under this Agreement. 
 8.    Solicitation of Employees. I agree that for a period of twelve (12) months immediately following the termination of my relationship with the Company for any reason,
whether voluntary or involuntary, with or without cause, I shall not either directly or indirectly solicit any of the Company’s employees to leave their employment, or attempt to solicit employees of the Company, either for myself or for any
other person or entity. 
 9.    Conflict of Interest Guidelines. I agree to diligently adhere to all
policies of the Company, including the Company’s insider’s trading policies and the Conflict-of-Interest Guidelines attached as Exhibit D hereto, which may be revised from time to time during my employment. 

10.    Representations. I agree to execute any proper oath or verify any proper document required to carry out
the terms of this Agreement. I represent that my performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the
Company. I hereby represent and warrant that I have not entered into, and I will not enter into, any oral or written agreement in conflict herewith. 
 11.    Audit. I acknowledge that I have no reasonable expectation of privacy in any computer, technology system, email, handheld device, telephone, or documents that are used to
conduct the business of the Company. As such, the Company has the right to audit and search all such items and systems, without further notice to me, to ensure that the Company is licensed to use the software on the Company’s devices in
compliance with the Company’s software licensing policies, to ensure compliance with the Company’s policies, and for any other business-related purposes in the Company’s sole discretion. I understand that I am not permitted to add any
unlicensed, unauthorized, or non-compliant applications to the Company’s technology systems and that I shall refrain from copying unlicensed software onto the Company’s technology systems or using non-licensed software or websites. I
understand that it is my responsibility to comply with the Company’s policies governing use of the Company’s documents and the internet, email, telephone, and technology systems to which I will have access in connection with my employment.

 12.    Arbitration and Equitable Relief. 

(a)    Arbitration. IN CONSIDERATION OF MY EMPLOYMENT WITH THE COMPANY, ITS PROMISE TO ARBITRATE ALL
EMPLOYMENT-RELATED DISPUTES, AND MY RECEIPT OF THE COMPENSATION, PAY RAISES, AND OTHER BENEFITS PAID TO ME BY THE COMPANY, AT PRESENT AND IN THE FUTURE, I AGREE THAT ANY AND ALL CONTROVERSIES, CLAIMS, OR DISPUTES WITH ANYONE (INCLUDING THE COMPANY
AND ANY EMPLOYEE, OFFICER, DIRECTOR, SHAREHOLDER, OR BENEFIT PLAN OF THE COMPANY, IN THEIR CAPACITY AS SUCH OR OTHERWISE), WHETHER BROUGHT ON AN INDIVIDUAL, OR CLASS BASIS, ARISING OUT OF, RELATING TO, OR RESULTING FROM MY EMPLOYMENT WITH THE
COMPANY OR THE TERMINATION 

  
 -5-

 
OF MY EMPLOYMENT WITH THE COMPANY, INCLUDING ANY BREACH OF THIS AGREEMENT, SHALL BE SUBJECT TO BINDING ARBITRATION UNDER THE ARBITRATION RULES SET FORTH IN CALIFORNIA CODE OF CIVIL PROCEDURE
SECTION 1280 THROUGH 1294.2, INCLUDING SECTION 1283.05 (THE “RULES”), AND PURSUANT TO CALIFORNIA LAW. DISPUTES THAT I AGREE TO ARBITRATE, AND THEREBY AGREE TO WAIVE ANY RIGHT TO A TRIAL BY JURY, INCLUDE ANY STATUTORY
CLAIMS UNDER LOCAL, STATE, OR FEDERAL LAW. INCLUDING, BUT NOT LIMITED TO, CLAIMS UNDER TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE OLDER WORKERS
BENEFIT PROTECTION ACT, THE SARBANES-OXLEY ACT, THE WORKER ADJUSTMENT AND RETRAINING NOTIFICATION ACT, THE CALIFORNIA FAIR EMPLOYMENT AND HOUSING ACT, THE FAMILY AND MEDICAL LEAVE ACT, THE CALIFORNIA FAMILY RIGHTS ACT, THE CALIFORNIA LABOR CODE,
CLAIMS OF HARASSMENT, DISCRIMINATION, AND WRONGFUL TERMINATION, AND ANY STATUTORY OR COMMON LAW CLAIMS. I FURTHER UNDERSTAND THAT THIS AGREEMENT TO ARBITRATE ALSO APPLIES TO ANY DISPUTES THAT THE COMPANY MAY HAVE WITH ME. 

(b)    Procedure. I AGREE THAT ANY ARBITRATION WILL BE ADMINISTERED BY JUDICIAL ARBITRATION &
MEDIATION SERVICES, INC. (“JAMS”), PURSUANT TO ITS EMPLOYMENT ARBITRATION RULES & PROCEDURES (THE “JAMS RULES”). I AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO DECIDE ANY MOTIONS BROUGHT BY ANY PARTY
TO THE ARBITRATION, INCLUDING MOTIONS FOR SUMMARY JUDGMENT AND/OR ADJUDICATION, MOTIONS TO DISMISS AND DEMURRERS, AND MOTIONS FOR CLASS CERTIFICATION, PRIOR TO ANY ARBITRATION HEARING. I ALSO AGREE THAT THE ARBITRATOR SHALL HAVE THE POWER TO AWARD
ANY REMEDIES AVAILABLE UNDER APPLICABLE LAW, AND THAT THE ARBITRATOR SHALL AWARD ATTORNEYS’ FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW. I UNDERSTAND THAT THE COMPANY WILL PAY FOR ANY ADMINISTRATIVE OR HEARING FEES
CHARGED BY THE ARBITRATOR OR JAMS EXCEPT THAT I SHALL PAY ANY FILING FEES ASSOCIATED WITH ANY ARBITRATION THAT I INITIATE, BUT ONLY SO MUCH OF THE FILING FEES AS I WOULD HAVE INSTEAD PAID HAD I FILED A COMPLAINT IN A COURT OF LAW. I AGREE THAT THE
ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN ACCORDANCE WITH CALIFORNIA LAW, INCLUDING THE CALIFORNIA CODE OF CIVIL PROCEDURE, AND THAT THE ARBITRATOR SHALL APPLY SUBSTANTIVE AND PROCEDURAL CALIFORNIA LAW TO ANY DISPUTE OR CLAIM,
WITHOUT REFERENCE TO RULES OF CONFLICT OF LAW. TO THE EXTENT THAT THE JAMS RULES CONFLICT WITH CALIFORNIA LAW, CALIFORNIA LAW SHALL TAKE PRECEDENCE. I AGREE THAT THE DECISION OF THE ARBITRATOR SHALL BE IN WRITING. I AGREE THAT ANY ARBITRATION UNDER
THIS AGREEMENT SHALL BE CONDUCTED IN SANTA CLARA COUNTY, CALIFORNIA. 

  
 -6-

 (c)    Remedy. EXCEPT AS PROVIDED BY THE RULES AND THIS
AGREEMENT, ARBITRATION SHALL BE THE SOLE, EXCLUSIVE, AND FINAL REMEDY FOR ANY DISPUTE BETWEEN ME AND THE COMPANY. ACCORDINGLY, EXCEPT AS PROVIDED FOR BY THE RULES AND THIS AGREEMENT, NEITHER I NOR THE COMPANY WILL BE PERMITTED TO PURSUE COURT ACTION
REGARDING CLAIMS THAT ARE SUBJECT TO ARBITRATION. NOTWITHSTANDING, THE ARBITRATOR WILL NOT HAVE THE AUTHORITY TO DISREGARD OR REFUSE TO ENFORCE ANY LAWFUL COMPANY POLICY, AND THE ARBITRATOR SHALL NOT ORDER OR REQUIRE THE COMPANY TO ADOPT A POLICY
NOT OTHERWISE REQUIRED BY LAW. NOTHING IN THIS AGREEMENT OR IN THIS PROVISION IS INTENDED TO WAIVE THE PROVISIONAL RELIEF REMEDIES AVAILABLE UNDER THE RULES. 
 (d)    Administrative Relief. I UNDERSTAND THAT THIS AGREEMENT DOES NOT PROHIBIT ME FROM PURSUING AN ADMINISTRATIVE CLAIM WITH A LOCAL, STATE, OR FEDERAL ADMINISTRATIVE BODY
SUCH AS THE DEPARTMENT OF FAIR EMPLOYMENT AND HOUSING, THE EQUAL EMPLOYMENT OPPORTUNITY COMMISSION, THE NATIONAL LABOR RELATIONS BOARD, OR THE WORKERS’ COMPENSATION BOARD. THIS AGREEMENT DOES, HOWEVER, PRECLUDE ME FROM PURSUING COURT ACTION
REGARDING ANY SUCH CLAIM. 
 (e)    Voluntary Nature of Agreement. I ACKNOWLEDGE AND AGREE THAT I AM
EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY THE COMPANY OR ANYONE ELSE. I FURTHER ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ THIS AGREEMENT AND THAT I HAVE ASKED ANY QUESTIONS NEEDED FOR ME TO UNDERSTAND
THE TERMS, CONSEQUENCES, AND BINDING EFFECT OF THIS AGREEMENT AND FULLY UNDERSTAND IT, INCLUDING THAT I AM WAIVING MY RIGHT TO A JURY TRIAL. FINALLY, I AGREE THAT I HAVE BEEN PROVIDED AN OPPORTUNITY TO SEEK THE ADVICE OF AN ATTORNEY OF
MY CHOICE BEFORE SIGNING THIS AGREEMENT. 
 13.    General Provisions. 

(a)    Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by the laws of the
State of California without giving effect to any choice-of-law rules or principles that may result in the application of the laws of any jurisdiction other than California. To the extent that any lawsuit is permitted under this Agreement, I hereby
expressly consent to the personal jurisdiction of the state and federal courts located in California for any lawsuit filed against me by the Company. 
 (b)    Entire Agreement. This Agreement, together with the Exhibits herein, sets forth the entire agreement and understanding between the Company and me relating to the subject
matter herein and supersedes all prior discussions or representations between us, including, but not limited to, any representations made during my interview(s) or relocation negotiations, whether written or oral. No modification of or amendment to
this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the President of the Company and me. Any subsequent change or changes in my duties, salary, or compensation will not affect the validity
or scope of this Agreement. 

  
 -7-

 (c)    Severability. If one or more of the provisions in this
Agreement are deemed void by law, then the remaining provisions will continue in full force and effect. 

(d)    Successors and Assigns. This Agreement will be binding upon my heirs, executors, assigns,
administrators, and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. There are no intended third-party beneficiaries to this Agreement, except as expressly stated. 

(e)    Waiver. Waiver by the Company of a breach of any provision of this Agreement will not operate as a
waiver of any other or subsequent breach. 
 (f)    Survivorship. The rights and obligations of the
parties to this Agreement will survive termination of my employment with the Company. 

(g)    Signatures. This Agreement may be signed in two counterparts, each of which shall be deemed an
original, with the same force and effectiveness as though executed in a single document. 

							
		 		 		 	
	Date:                          
                                         
              	 		 		 	 
		 		 		 	Signature

  

							
		 		 		 	 
		 		 		 	Name of Employee (typed or printed)
	Witness:	 		 		 	
				
		 		 		 	
	Signature	 		 		 	
				
		 		 		 	
	Name (typed or printed)	 		 		 	

  
 -8-

 Exhibit A 

LIST OF PRIOR INVENTIONS 
 AND ORIGINAL WORKS OF AUTHORSHIP 
  

					
	 Title
	 	 Date
	 	 Identifying Number or

Brief Description

  

              No inventions or improvements 

              Additional Sheets Attached 

 

			
	 Signature of Employee: 
	 	 
		
	 Print Name of Employee: 
	 	 

  

			
	 Date: 
	 	 

  
 A-1

 Exhibit B 

CALIFORNIA LABOR CODE SECTION 2870 
 INVENTION ON OWN TIME-EXEMPTION FROM AGREEMENT 

“(a)    Any provision in an employment agreement which provides that an employee shall assign, or offer to
assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret
information except for those inventions that either: 
 (1)    Relate at the time of conception or reduction
to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or 
 (2)    Result from any work performed by the employee for the employer. 
 (b)    To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under
subdivision (a), the provision is against the public policy of this state and is unenforceable.” 

  
 B-1

 Exhibit C 

EXTEND HEALTH, INC. 
 TERMINATION CERTIFICATION 
 This is to certify that I do not have in my
possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, any other documents or property, or reproductions of any and
all aforementioned items belonging to Extend Health, Inc., its subsidiaries, affiliates, successors or assigns (together, the “Company”). 
 I further certify that I have complied with all the terms of the Company’s At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement signed by me, including the
reporting of any inventions and original works of authorship (as defined therein) conceived or made by me (solely or jointly with others), as covered by that agreement. 
 I further agree that, in compliance with the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, I will preserve as confidential all Company Confidential
Information and Associated Third Party Confidential Information, including trade secrets, confidential knowledge, data, or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental
work, computer programs, databases, other original works of authorship, customer lists, business plans, financial information, or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants, or
licensees. 
 I also agree that for twelve (12) months from this date, I will not either directly or indirectly solicit,
induce, recruit, or encourage any of the Company’s employees to leave their employment, or to enter into an employment, consulting, contractor, or other relationship with any other person, firm, business entity, or organization (including with
myself). 
 After leaving the Company’s employment, I will be employed by ______________________ in the position of:
_________________________________________________________________. 
  

							
		 		 		 	 
		 		 		 	Signature of employee

  

							
		 		 		 	 
		 		 		 	Print name

  

							
		 		 		 	 
		 		 		 	Date

  

							
	Address for Notifications:	 		 		 	 
		 		 		 	

  
 C-1

 Exhibit D 

EXTEND HEALTH, INC. 
 CONFLICT-OF-INTEREST GUIDELINES 
 It is the policy of Extend Health, Inc.
to conduct its affairs in strict compliance with the letter and spirit of the law and to adhere to the highest principles of business ethics. Accordingly, all officers, employees, and independent contractors must avoid activities that are in
conflict, or give the appearance of being in conflict, with these principles and with the interests of the Company. The following are potentially compromising situations that must be avoided: 

1.    Revealing confidential information to outsiders or misusing confidential information. Unauthorized divulging of
information is a violation of this policy whether or not for personal gain and whether or not harm to the Company is intended. (The At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement elaborates on this
principle and is a binding agreement.) 
 2.    Accepting or offering substantial gifts, excessive
entertainment, favors, or payments that may be deemed to constitute undue influence or otherwise be improper or embarrassing to the Company. 
 3.    Participating in civic or professional organizations that might involve divulging confidential information of the Company. 

4.    Initiating or approving personnel actions affecting reward or punishment of employees or applicants where there
is a family relationship or is or appears to be a personal or social involvement. 
 5.    Initiating or
approving any form of personal or social harassment of employees. 
 6.    Investing or holding outside
directorship in suppliers, customers, or competing companies, including financial speculations, where such investment or directorship might influence in any manner a decision or course of action of the Company. 

7.    Borrowing from or lending to employees, customers, or suppliers. 

8.    Acquiring real estate of interest to the Company. 

9.    Improperly using or disclosing to the Company any proprietary information or trade secrets of any former or
concurrent employer or other person or entity with whom obligations of confidentiality exist. 

10.    Unlawfully discussing prices, costs, customers, sales, or markets with competing companies or their employees.

  
 D-1

 11.    Making any unlawful agreement with distributors with respect to
prices. 
 12.    Improperly using or authorizing the use of any inventions that are the subject of patent
claims of any other person or entity. 
 13.    Engaging in any conduct that is not in the best interest of
the Company. 
 Each officer, employee, and independent contractor must take every necessary action to ensure compliance with
these guidelines and to bring problem areas to the attention of higher management for review. Violations of this conflict-of-interest policy may result in discharge without warning. 

  
 D-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]